Purpose. The purpose of this pilot study was to examine arachidonate 5-lipoxygenase (ALOX5) and ALOX5-activating protein (ALOX5AP) gene variations in patients with and without acute coronary syndrome (ACS). Methodology. Four and six single nucleotide polymorphisms spanning the ALOX5 and ALOX5AP genes, respectively, were genotyped in 19 non-Hispanic Caucasian patients with ACS and 27 controls. Results. Presence of the common allele of rs9508835 (ALOX5AP) and the minor allele of rs2029253 (ALOX5) were associated with ACS. After adjustment for age, being a carrier of the rs9508835 common allele was associated with an increased risk of ACS (odds ratio = 2.86). Relevance for nursing practice. Through the inhibition of the ALOX5AP gene by downregulation of the leukotriene pathway, the risk of ACS may be decreased in individuals that carry susceptibility allele(s). Knowledge of the genetic basis of treatments that downregulate the leukotriene pathway may prove essential to the care of individuals with ACS.
Aiello, R.J., Bourassa, P.A., Lindsey, S., Weng, W., Freeman, A., & Showell, H.J. (2002). Leukotriene B4 receptor antagonism reduces monocytic foam cells in mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 22, 443-449.
2.
Albert, C.M., Ma, J., Rifai, N., Stampfer, M.J., & Ridker, P.M. (2002). Prospective study of C-reactive protein, homocysteine, and plasma lipid levels as predictors of sudden cardiac death. Circulation, 105, 2595-2599.
3.
Barrett, J.C., Fry, B., Maller, J., & Daly, M.J. (2005). Haploview: Analysis and visualization of lD and haplotype maps. Bioinformatics, 21, 263-265.
4.
Bots, M.L., Hofman, A., & Grobbee, D.E. (1997). Increased common carotid intima-media thickness. Adaptive response or a reflection of atherosclerosis? Findings from the Rotterdam study. Stroke, 28, 2442-2447.
5.
Braunwald, E. (1997). Shattuck lecture: Cardiovascular medicine at the turn of the millennium: Triumphs, concerns, and opportunities. New England Journal of Medicine, 337, 1360-1369.
Dahlen, S.E., Hedqvist, P., Hammarstrom, S., & Samuelsson, B. (1980). Leukotrienes are potent constrictors of human bronchi. Nature, 288, 484-486.
8.
De Caterina, R., & Zampolli, A. (2004). From asthma to atherosclerosis: 5-Lipoxygenase, leukotrienes, and inflammation. New England Journal of Medicine , 350, 4-7.
9.
Drazen, J.M., Israel, E., & O'Byrne, P.M. (1999). Treatment of asthma with drugs modifying the leukotriene pathway. New England Journal of Medicine, 340, 197-206.
10.
Dwyer, J.H., Allayee, H., Dwyer, K.M., Fan, J., Wu, H., Mar, R., et al. (2004). Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis. New England Journal of Medicine, 350, 29-37.
11.
Funk, C.D., Hoshiko, S., Matsumoto, T., Rdmark, O., & Samuelsson, B. (1989). Characterization of the human 5-lipoxygenase gene. Proceedings of the National Academy of Sciences of the United States of America, 86, 2587-2591.
12.
Gorelik, O., Almoznino-Sarafian, D., Yarovoi, I., Alon, I., Shteinshnaider, M., Chachashvily, S., et al. (2006). Patient-related variables predicting acute coronary syndrome following admission for chest pain of possible coronary origin. Coronary Artery Disease, 17, 15-21.
13.
Harris, T.B., Ferrucci, L., Tracy, R.P., Corti, M.C., Wacholder, S., Ettinger, W.H., Jr. , et al. (1999). Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. American Journal of Medicine, 106, 506-512.
14.
Hasdai, D., Behar, S., Wallentin, L., Danchin, N., Gitt, A.K., Boersma, E., et al. (2002). A prospective survey of the characteristics, treatments and outcomes of patients with acute coronary syndromes in Europe and the Mediterranean basin; the Euro heart survey of acute coronary syndromes (Euro heart survey ACS). European Heart Journal, 23, 1190-1201.
15.
Helgadottir, A., Gretarsdottir, S., St Clair, D., Manolescu, A., Cheung, J., Thorleifsson, G., et al. (2005). Association between the gene encoding 5-lipoxygenase-activating protein and stroke replicated in a Scottish population. American Journal of Human Genetics, 76, 505-509.
16.
Helgadottir, A., Manolescu, A., Thorleifsson, G., Gretarsdottir, S., Jonsdottir, H., Thorsteinsdottir, U., et al. (2004). The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nature Genetics, 36, 233-239.
17.
Hoshiko, S., Radmark, O., & Samuelsson, B. (1990). Characterization of the human 5-lipoxygenase gene promoter. Proceedings of the National Academy of Sciences of the United States of America, 87, 9073-9077.
18.
Kajimoto, K., Shioji, K., Ishida, C., Iwanaga, Y., Kokubo, Y., Tomoike, H., et al. (2005). Validation of the association between the gene encoding 5-lipoxygenase-activating protein and myocardial infarction in a Japanese population. Circulation Journal, 69, 1029-1034.
Mehrabian, M., Allayee, H., Wong, J., Shi, W., Wang, X.P., Shaposhnik, Z., et al. (2002). Identification of 5-lipoxygenase as a major gene contributing to atherosclerosis susceptibility in mice. Circulation Research, 91, 120-126.
21.
Pearson, T.A., Mensah, G.A., Alexander, R.W., Anderson, J.L., Cannon, R.O., 3rd, Criqui, M., et al. (2003). Markers of inflammation and cardiovascular disease: Application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation, 107, 499-511.
22.
Ridker, P.M., Buring, J.E., Shih, J., Matias, M., & Hennekens, C.H. (1998). Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation, 98, 731-733.
23.
Ridker, P.M., Cushman, M., Stampfer, M.J., Tracy, R.P., & Hennekens, C.H. (1997). Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. New England Journal of Medicine, 336, 973-979.
24.
Ridker, P.M., Stampfer, M.J., & Rifai, N. (2001). Novel risk factors for systemic atherosclerosis: A comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease . New England Journal of Medicine, 285, 2481-2485.
25.
Ross, R., & Glomset, J.A. (1976a). The pathogenesis of atherosclerosis (first of two parts). New England Journal of Medicine, 295, 369-377.
26.
Ross, R., & Glomset, J.A. (1976b). The pathogenesis of atherosclerosis (second of two parts). New England Journal of Medicine, 295, 420-425.
27.
Spanbroek, R., Grabner, R., Lotzer, K., Hildner, M., Urbach, A., Ruhling, K., et al. (2003). Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis. Proceedings of the National Academy of Sciences of the United States of America , 100, 1238-1243.
28.
Steg, P.G., Goldberg, R.J., Gore, J.M., Fox, K.A., Eagle, K.A., Flather, M.D., et al. (2002). Baseline characteristics, management practices, and in-hospital outcomes of patients hospitalized with acute coronary syndromes in the global registry of acute coronary events (GRACE). American Journal of Cardiology, 90, 358-363.
29.
Stephens, M., Smith, N.J., & Donnelly, P. (2001). A new statistical method for haplotype reconstruction from population data. American Journal of Human Genetics, 68, 978-989.
30.
Yen, M.H., Bhatt, D.L., Chew, D.P., Harrington, R.A., Newby, L.K., Ardissino, D., et al. (2003). Association between admission white blood cell count and one-year mortality in patients with acute coronary syndromes . American Journal of Medicine, 115, 318-321.
